Cargando…

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasi, Pashtoon M., Fehringer, Gordon, Taniguchi, Hiroya, Starling, Naureen, Nakamura, Yoshiaki, Kotani, Daisuke, Powles, Thomas, Li, Bob T., Pusztai, Lajos, Aushev, Vasily N., Kalashnikova, Ekaterina, Sharma, Shruti, Malhotra, Meenakshi, Demko, Zachary P., Aleshin, Alexey, Rodriguez, Angel, Billings, Paul R., Grothey, Axel, Taieb, Julien, Cunningham, David, Yoshino, Takayuki, Kopetz, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926064/ https://www.ncbi.nlm.nih.gov/pubmed/35263168 http://dx.doi.org/10.1200/PO.21.00181

Ejemplares similares

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2021)

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
por: Huffman, Brandon M., et al.
Publicado: (2022)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies
por: Kasi, Pashtoon Murtaza
Publicado: (2022)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
por: Kasi, Pashtoon Murtaza
Publicado: (2020)

Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study
por: Wang, Cassia B., et al.
Publicado: (2019)

Neuroendocrine Tumor Involving the Epicardium
por: Soyano, Aixa E., et al.
Publicado: (2017)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer
por: Kamatham, Saivaishnavi, et al.
Publicado: (2020)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
por: Shahjehan, Faisal, et al.
Publicado: (2019)

Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence
por: Soyano, Aixa E., et al.
Publicado: (2019)

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse
por: Dhakal, Binod, et al.
Publicado: (2022)

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy
por: Lutfi, Areeb, et al.
Publicado: (2023)

Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
por: Malla, Midhun, et al.
Publicado: (2022)

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2015)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report
por: Azzi, Georges, et al.
Publicado: (2022)

ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden
por: Schneider, Charles J., et al.
Publicado: (2021)

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2023)

The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant
por: Cohen, Stacey A., et al.
Publicado: (2022)

Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011)

Malignant Hyperthermia and Idiopathic HyperCKemia
por: Kasi, Pashtoon Murtaza
Publicado: (2011)

The Use of Intravenous Neostigmine in Palliation of Severe Ileus
por: Kasi, Pashtoon Murtaza
Publicado: (2013)

Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
por: Kasi, Pashtoon Murtaza
Publicado: (2022)

Types of Liquid Biopsies: Understanding the Different Lenses Through Which They Can Detect Cancer
por: Kasi, Pashtoon Murtaza
Publicado: (2023)

Editorial: Case reports in gastrointestinal cancers : 2022
por: Kasi, Pashtoon Murtaza
Publicado: (2023)

Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection
por: Ococks, Emma, et al.
Publicado: (2021)

Rituximab and Cytokine Release Syndrome
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2012)

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma
por: Alsidawi, Samer, et al.
Publicado: (2018)

Diverse immune response of DNA damage repair-deficient tumors
por: Qing, Tao, et al.
Publicado: (2021)

Birt-Hogg-Dubé Syndrome: Answering Questions Raised by a Case Report Published in 1962
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2011)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Excessive Work Hours of Physicians in Training: Maladaptive Coping Strategies
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2007)

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
por: Hsiehchen, David, et al.
Publicado: (2022)

Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer
por: Weinberg, Benjamin A., et al.
Publicado: (2021)

Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
por: Hsiehchen, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m25rui7fpf5danrpuul322b98o